Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT61 nasal formulations plus chlorhexidine washes in nasal Staphylococcus aureus carriers
2010-021193-11Phase 2Completed
- Sponsor
- Helperby Therapeutics
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HT61 in Staphylococcus aureus nasal carriage, nasal carriage of methicillin-resistant Staphylococcus aureus and staphylococcal carrier state (3 arms), sponsored by Helperby Therapeutics. Primary endpoints: Nasal decolonisation of Staphylococcus aureus and Safety and tolerability of HT61. Started Aug 2010; status: completed.
02
Drugs
HT61
03
Conditions
Staphylococcus aureus nasal carriagenasal carriage of methicillin-resistant Staphylococcus aureusstaphylococcal carrier state
Beyond the preview
Go deeper on 2010-021193-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021193-11.